REPRICING PRESSURE
Opaque methodologies and algorithmic reductions suppressed payments.
VIP Medical Group · Arbitration opinion · July 2026
Arbitration will evolve.
It is unlikely to disappear.
Our opinion: the No Surprises Act created a durable dispute-resolution architecture. Its economic value belongs to operators who convert eligible claims into collected cash—not those who merely accumulate awards.
IDR AS AN ECONOMIC ENGINE Underwritten
ENTRY6.0×
EFFECTIVE4.0×
PAYBACK68 mo.39 months sooner
5-YR IRR22.1%from 12.2%
RUN-RATE LIFT$1.4Mannual contribution
IDR AR PROXY$1.0Mcash that must be financed
01
A 6.0× clinic only behaves like a 4.0× investment after the whole cash funnel works.
01FREE MARKET OONNegotiated, opaque,
relationship-driven
relationship-driven
02PAYER REPRICINGSuppressed payments,
widening friction
widening friction
03REGULATED IDRPatient protected,
bounded process
bounded process
Designed mechanism—not a workaround.
VALUE
OON upside is conditional on eligibility and realization.
DURABILITY
Patient protection is the mechanism’s political anchor.
ADVANTAGE
Scale compounds only when data and controls improve.
What is the No Surprises Act?
The patient exits the dispute.
A regulated pricing lane begins.
The No Surprises Act limits surprise billing in protected situations and moves qualifying provider–plan payment disputes into open negotiation and, when necessary, certified independent dispute resolution.
01Protect the patientNo balance-billing fight at the bedside.
02NegotiateProvider and plan attempt resolution first.
03ResolveEligible disputes proceed through certified IDR.
Acquisition value simulator
One clinic.
Two earnings curves.
Move the inputs. The model carries candidate volume through eligibility, resolution, collection lag and terminal-value credit—then recalculates payback, effective multiple and IRR.
01
Deal + claim engine
Illustrative inputs · edit freely
Acquisition
Eligibility + resolution
Cash timing + exit assumptions +
ALL-IN INVESTMENT$15.75M
Live outputEFFECTIVE ENTRY MULTIPLE4.03×
Entry was 6.0× baseline EBITDA.
5-YEAR UNLEVERED IRR22.1%
As-is: 12.2% · +9.9%
MONTHS SAVED39
107 → 68 month payback
RUN-RATE IDR LIFT$1.4M
after filing + fixed costs
MOIC2.19×
as-is 1.59×
PEAK CASH NEED$265K
modeled pre-collection burn
Terminal-value proof50% credit
At exit, the model credits only 50% of run-rate IDR earnings. Move this in “Cash timing + exit” to see how much of the return depends on the next buyer believing the story.
RETURN GATE9% eligible
minimum file-ready share for IDR IRR to meet the as-is case at current assumptions
COLLECTION GATE28% realized
minimum payment realization for IDR IRR to meet the as-is case at current assumptions
01THE VALUE LANDSCAPE
Scale in context
Nationally small.
Locally material.
The original opinion is directionally right that IDR is small relative to U.S. healthcare. The arithmetic is corrected here: small system-wide exposure can still create meaningful economics inside a concentrated provider cohort.
TOTAL HEALTH SPEND$5.6T2026 deck-context estimate
OON SPEND$150–200Bdeck-context estimate
ESTIMATED IDR COST$4.6B≈0.082% of total spend
IDR SHARE OF CLAIMS0.05–0.06%3.2M of 5–6B submissions
ORIGINAL POV COMPARISON
The thesis is measured value—not maximum value.
The deck positions VIP’s awards below several headline operators. That comparison belongs in the opinion, but not in the acquisition model until the cohorts, CPTs, dates and denominators are normalized.
02WHY ARBITRATION EXISTS
How OON degraded
When cooperation broke.
The patient absorbed the friction.
Opaque repricing compressed payments. Providers responded by protecting revenue through higher charges and negotiation. The widening gap ultimately exposed patients—making a protected, repeatable dispute mechanism politically necessary.
PROVIDER RESPONSE
Providers raised charges and sought leverage against unpredictable reimbursement.
WIDENING GAP
Charges and allowed amounts diverged while disputes grew more adversarial.
PATIENT EXPOSURE
Balance-billing risk moved the problem from commercial friction to public policy.
THE NSA RESPONSERemove the patient. Preserve the dispute. Define the lane.
The payer paradox
Arbitration creates a bounded negotiation zone.
It is neither legacy payer suppression nor automatic payment of billed charges. The QPA remains a required input; permitted, credible claim-specific evidence can support a different offer. Billed charges and usual-and-customary rates are prohibited factors.
Federal IDR final rule ↗PAYER-DICTATED FLOORlow or zero paymentsEVIDENCE-BASED IDRdefined process, bounded offersFULL BILLED CHARGEnot the governing standard
QPA + permitted claim-specific evidence
BEFOREInconsistent · opaque · payer-controlled
Third-party repricing and ad hoc negotiation produced unpredictable gaps.
AFTERDefined · bounded · repeatable
Open negotiation and certified IDR make the dispute legible without putting the patient back inside it.
Conditional provider advantage
OON can create stronger economics.
It also creates harder cash dynamics.
Static in-network contracts can lag inflation and operating cost. OON preserves a claim-specific challenge path—but adds eligibility risk, administrative cost, payment volatility and working-capital exposure.
PROVIDER
Potential reimbursement upside
More pricing leverage and claim-specific evidence, offset by filing cost, rejection risk, DSO and collections.
PLAN
Bounded dispute exposure
A defined process replaces uncontrolled patient billing, but adds IDR administration and determination expense.
PATIENT
Protected cost sharing
The patient receives care without becoming the collection mechanism for a provider–plan disagreement.
ORIGINAL EXAMPLE, REFRAMED$10,000 billeddoes not equal economic value
IN-NETWORK ALLOWED$1,800illustrative contracted rate
OON ALLOWED$2,500illustrative resolved amount
The economically relevant provider delta is $700. The $7,500 difference from gross charges is not payer “savings,” and any TPA fee must be modeled separately.
03THE DURABILITY OPINION
Why VIP believes the mechanism endures
Three anchors make repeal less likely than evolution.
This is an expert judgment, not a certainty. The strongest conclusion is that the architecture is durable because it solves a persistent policy problem; its pricing, batching, procedure and enforcement rules will continue to change.
Patient protection is difficult to unwind.
The NSA’s central promise is to keep patients out of certain surprise-billing disputes. That creates a durable constituency for a replacement mechanism.
STRONGEST ANCHORPlans and providers still need a price-setting channel.
When network contracts do not govern, a negotiated or adjudicated process must allocate payment risk somewhere.
STRUCTURAL NEEDThe operating infrastructure is already embedded.
Certified IDR entities, federal rules, reporting, portal workflows, payer compliance systems and trained operators create switching costs.
INSTITUTIONAL MOMENTUMVIP OPINIONThe mechanism is likely to standardize—not vanish.
Expect lower friction, tighter rules, more transparency and continued disputes over payment and enforcement.
How arbitration is evolving
From emergency rulemaking
toward operating infrastructure.
Standardization is real, but “clearinghouse” remains a future-state analogy. The most recent changes improve process visibility; they do not guarantee payment or eliminate legal challenge.
Evidence framework
The QPA remains required while credible, permitted additional information may influence selection.
Rule ↗Provider offers selected often
CMS reports 88% in payment determinations—not an 88% recovery rate, and not proof of collection.
CMS data ↗Narrow review; split enforcement
Determinations are binding with limited vacatur grounds, while courts remain divided on private enforcement of unpaid awards.
Fifth Circuit ↗Phased operations upgrade
Lower fees, clearer remittance signals, batching, registry and portal changes arrive on different implementation dates.
CMS fact sheet ↗LEGAL BOTTOM LINEBinding does not mean unchallengeable. Awarded does not mean paid.
Key arbitration risks
Scale is an advantage
only when the controls work.
The original opinion treats every risk as a moat. The stronger view is conditional: complexity can concentrate value in scaled operators, but it also multiplies bad eligibility logic, deadline errors and working-capital exposure.
RATE NORMALIZATION
Awards may compress from headline levels.
Higher payment realization can offset lower face value—but only if cohort cash proves it.BASE OON PRESSURE
Underlying OON rates may continue to decline.
IDR must create a repeatable collected spread after all variable and fixed costs.COMPLEXITY
Rules, entities and payer tactics will keep changing.
Scale helps only with evidence, clocks, owners, exceptions and postmortems.VOLUME CONTROLS
Batching and filing rules can increase friction.
Automation reduces marginal work; eligibility, notices and filings remain human-approved.ADVERSE RULINGS
Payers retain narrow statutory challenge routes.
Model legal review and payment enforcement separately; do not assume no recourse.WORKING CAPITAL
Long DSO can make accounting wins economically weak.
Finance awarded-but-unpaid AR explicitly and underwrite payer-specific collection curves.ORIGINAL INTERNAL OBSERVATION“55% paid on won cases”
Potentially the most important number in the deck—and not yet safe for external underwriting without a dated cohort, dollar-weighted denominator and payment-status reconciliation.
The conversion chain
Not every claim
becomes IDR cash.
Each bar is a separate underwriting gate. The model never applies a national win rate to raw clinic volume.
01
Candidate claims screenedpotentially relevant OON claims / mo.
200
02
Eligible + file-ready35% pass human review
70.0
03
Favorable resolutions60% modeled rate
42.0
04
Cash-realized wins80% paid-on-win
33.6
Annual run-rate contribution$1.4M70 eligible claims / month · $2K expected contribution / filed claim
04THE OPERATING ADVANTAGE
VIP’s strategic advantage
Speed matters.
Proof matters more.
VIP’s thesis is that it can adapt faster than average providers. The investable version of that claim pairs each advantage with a current signal, a target capability and the evidence required to believe it.
QUALITYAVERAGE PROVIDERVIP CURRENT SIGNALPROOF REQUIRED
Filing cadenceEpisodic, reactiveSystemized routing lane existsOn-time file rate by cohort
Cost per caseHigh administrative burdenAutomation already supports documents and workflowAudited fully loaded cost per filing
Data trackingLimited payer/CPT feedbackSnowflake intake + operational trackingPaid recovery by payer, CPT, state and entity
Rule changesSlow process adaptationWorkflows and templates can be revisedChange log + error-rate trend
Cash flowAccepts quick discounts to protect liquidityAward and payment tracking are separate prioritiesCollection curve + funded peak cash need
Objections / appealsReworks each case at high costTaxonomy and drafting can be system-assistedHuman-approved response quality + outcomes
Why VIP can win in arbitration
The advantage compounds
when every case teaches.
More volume is useful only when every handoff leaves an auditable artifact, an owner, a next clock and a postmortem that changes the next submission.
Proof
EOB + proof of payment before the claim enters the lane.
Route
State, funding, setting, network status and deadline reviewed.
File
Evidence packet and offer approved; counsel joins where required.
Resolve
Outcomes segmented by payer, CPT, state and IDR entity.
Collect
Award, paid amount and enforcement path tracked separately.
01VOLUMEmore eligible, evidence-complete claims
→02DATApayer, CPT, state and entity outcomes
→03SYSTEMIZATIONbetter routing, packets and exception handling
→04PERFORMANCElower leakage, faster cash, investable cohorts
CLAIM INTELLIGENCE · THE COMPOUNDING ADVANTAGE
Volume becomes valuable only when the system learns.
More well-routed claims create payer/CPT/IDR-entity evidence. That sharpens packets, reduces leakage, accelerates cash and expands the next investable cohort.
CAPABILITYCURRENT SIGNALACQUISITION UNLOCKCONTROL THAT STAYS HUMAN
Claim identificationWorkflow existsMore screened cohortsRoute + eligibility review
Filing throughputSystemized laneHigher qualified volumeEvidence + offer approval
Legal productionExternal laneTighter handoffsCounsel where required
CollectionsTracked separatelyPayer-cohort evidenceAward ≠ cash
Medwork in arbitration
A closed-loop operating system.
Not a no-touch promise.
Medwork is the intended target surface. Today, Snowflake is the warehouse, ClickUp is a read-only bridge, Elite handles eligible new IDR inventory, and counsel and collections remain distinct lanes.
WAREHOUSESNOWFLAKEclaim intake + source data
→CURRENT BRIDGECLICKUPorganization + workflow visibility
→TARGET SURFACEMEDWORKtransactional queues + decision support
01EOB / PROOFFirst readiness gate
02ROUTEFunding, state, setting, network
03PACKETEvidence + deadline control
04NEGOTIATEOpen-negotiation workflow
05FILE / COUNSELHuman-approved production lane
06DETERMINEOutcome + substantiation
07COLLECTAwarded versus paid
08LEARNPostmortem by payer/CPT/entity
TARGETFewer manual handoffs
Every transition preserves owner, artifact and next action.
TARGETDeadline protection
Visible clocks and escalation reduce preventable expiration.
TARGETLower process leakage
Exceptions remain visible instead of disappearing inside automation.
HUMAN GATEExpected-value ranking
Prioritize only after eligibility, route and evidence are approved.
Investment committee close
The opinion is durable.
The value is conditional.
Arbitration can improve clinic economics when the eligible cohort, cash realization, operating control and working-capital capacity are real. It cannot rescue a weak claim mix or a bad entry price.
Stress the scenario ↑01The mechanism persists
Patient protection keeps a provider–plan resolution channel necessary.
02Rates normalize
Value shifts from maximum awards toward repeatable paid outcomes.
03Scale concentrates
Complexity favors operators with evidence, clocks, data and funded AR.
04Cash decides
Only collected, cohort-proven earnings should reduce the effective multiple.
14.3eligible claims / month to cover fixed IDR cost
$1.0Msteady-state IDR receivables proxy
50%of new earnings credited at exit
65%of baseline EBITDA converted to modeled free cash flow
Method + boundary
Illustrative, unlevered acquisition model. Operating payback uses cumulative baseline free cash flow at the selected conversion rate plus modeled IDR cash; exit value is excluded from payback. IDR cash is already modeled after payment realization, filing cost and fixed operating cost. “Effective multiple” divides all-in investment by baseline EBITDA plus steady-state IDR contribution. Real underwriting should use payer-specific cohorts and a collection curve.
Legal + evidence controls
Eligibility and jurisdiction remain claim-specific, human/legal-approved gates. A favorable IDR determination is binding subject to narrow statutory review, but it is not proof of collection. This experience is not legal or investment advice.